The Medicines Co (The Medicines Co) EPS Growth Rate (Future 3Y To 5Y Estimate) : 37.00 (As of May. 05, 2024)

View and export this data going back to 2000. Start your Free Trial

What is The Medicines Co EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, The Medicines Co's EPS Growth Rate (Future 3Y To 5Y Estimate) is 37.00.

Competitive Comparison of The Medicines Co's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Drug Manufacturers - Specialty & Generic subindustry, The Medicines Co's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Medicines Co's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, The Medicines Co's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where The Medicines Co's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

The Medicines Co (NAS:MDCO) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

The Medicines Co EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of The Medicines Co's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

The Medicines Co (The Medicines Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » The Medicines Co (NAS:MDCO) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Traded in Other Exchanges

N/A

Address

8 Sylvan Way, Parsippany, NJ, USA, 07054

Website

https://www.themedicinescompany.com

The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.

Executives

Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Peter Wijngaard	officer: Chief Development Officer	8 SYLVAN WAY, PARSIPPANY NJ 07054
Paris Panayiotopoulos	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Geno J Germano	director	5 GIRALDA FARMS, MADISON NJ 07940
Sarah J. Schlesinger	director	C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christopher T Cox	officer: EVP & Chief Corp. Dev. Officer	CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281
Fredric N Eshelman	director, officer: Executive Chairman	PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Armin M Kessler	director
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Hiroaki Shigeta	director	THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Stuart A Kingsley	officer: President and COO	152 CHESTNUT STREET, WEST NEWTON MA 02465
Robert G. Savage	director	C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Glenn Sblendorio	director, officer: President & CFO	3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
James E Flynn	10 percent owner, other: Possible Members of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C)	10 percent owner, other: Possible Members of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010